PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.\', \'Cleveland Clinic Florida Research & Innovation Center, Port St. Lucie, Florida 34987, United States.\', \'Department of Pharmaceutical Science, Lipscomb University College of Pharmacy, Nashville, Tennessee 37204, United States.\', \'Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.\', \'Center for Global and Emerging Pathogens Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1021/acs.jmedchem.1c00598
?:doi
?:hasPublicationType
?:journal
  • Journal of medicinal chemistry
is ?:pmid of
?:pmid
?:pmid
  • 34347470
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.567
?:rankingScore_hIndex
  • 231
?:title
  • Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro).
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34347470>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34347470>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all